STAT+: A patent win for Pfizer and BridgeBio
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Chiesi to acquire KalVista Therapeutics for $1.9 billion, valuing KalVista at $27 per share, a 40 % premium to its Tuesday close.
- FDA will start real‑time review of oncology trial data, beginning with AstraZeneca and Amgen studies.
- Biogen posted first‑quarter earnings, alongside AstraZeneca, Regeneron, AbbVie and GSK.
Why it matters: Chiesi gains a new rare‑disease drug and a foothold in hereditary angioedema, while shareholders see a 40 % premium boost; FDA’s real‑time review will accelerate oncology approvals, reshaping market timelines.
